The invention relates to the use of treosulfan as a conditioning agent
before allogenic transplantation of bone marrow or haematopoietic stem
cells, whereby treosulfan is administered, either as single effective
agent, or in combination with other chemotherapetic agents or
immunosuppressant agents.